Robert J. Soiffer
#131,123
Most Influential Person Now
Robert J. Soiffer's AcademicInfluence.com Rankings
Robert J. Soifferphilosophy Degrees
Philosophy
#6370
World Rank
#9399
Historical Rank
Logic
#3548
World Rank
#4729
Historical Rank
Download Badge
Philosophy
Robert J. Soiffer's Degrees
- Doctorate Medicine Harvard University
Why Is Robert J. Soiffer Influential?
(Suggest an Edit or Addition)Robert J. Soiffer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003) (979)
- Interleukin-2 and regulatory T cells in graft-versus-host disease. (2011) (953)
- Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009) (773)
- IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. (2006) (725)
- Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. (2014) (648)
- Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. (1998) (591)
- Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. (2010) (526)
- Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. (2010) (455)
- Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. (2005) (450)
- The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. (2001) (422)
- Rituximab for steroid-refractory chronic graft-versus-host disease. (2006) (411)
- Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease (2013) (402)
- Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. (2004) (384)
- Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. (2005) (383)
- Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. (1999) (371)
- Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation (2014) (368)
- Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. (2014) (344)
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults. (2007) (331)
- Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. (2011) (328)
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. (2009) (315)
- Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. (2002) (312)
- A disease risk index for patients undergoing allogeneic stem cell transplantation. (2012) (305)
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. (2004) (301)
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. (2009) (300)
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. (2003) (299)
- Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. (2003) (298)
- Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. (2013) (291)
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation. (2016) (285)
- Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. (2014) (276)
- Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. (2017) (270)
- Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. (2013) (267)
- Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. (2007) (265)
- Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. (1993) (265)
- Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. (2010) (223)
- High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease (2007) (223)
- Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. (2016) (222)
- Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. (2010) (222)
- Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. (2005) (219)
- Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. (2017) (216)
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (213)
- Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. (2014) (206)
- Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. (2002) (205)
- Quality of life associated with acute and chronic graft-versus-host disease (2006) (205)
- High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. (2007) (203)
- Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. (1992) (202)
- Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. (2017) (198)
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. (2004) (187)
- Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. (2006) (186)
- Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. (2007) (184)
- Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. (2003) (184)
- Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation (2004) (181)
- Renal failure associated with cancer and its treatment: an update. (2004) (179)
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. (2017) (177)
- Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. (2002) (174)
- Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. (2011) (173)
- Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. (2014) (171)
- Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. (2016) (170)
- Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD (2010) (170)
- Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. (2004) (163)
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma (2018) (161)
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission (2016) (158)
- Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. (2011) (157)
- Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. (2005) (154)
- Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. (1994) (154)
- Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. (2003) (152)
- Recovery after stem-cell transplantation for hematologic diseases. (2001) (151)
- A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. (1995) (150)
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. (2014) (148)
- Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. (2001) (146)
- Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. (1992) (144)
- Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. (2008) (142)
- Routine screening for psychosocial distress following hematopoietic stem cell transplantation (2005) (142)
- Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma (2002) (141)
- Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. (2012) (139)
- Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. (2004) (139)
- Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. (2016) (139)
- Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. (2012) (138)
- Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (2004) (137)
- Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. (2007) (134)
- Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. (2013) (133)
- Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. (2007) (133)
- Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. (2010) (128)
- PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. (2017) (128)
- Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (2011) (128)
- Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. (2012) (127)
- Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. (2000) (126)
- Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. (2011) (122)
- Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. (2008) (121)
- Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. (1991) (118)
- Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. (1993) (116)
- Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. (2011) (114)
- Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis (2011) (113)
- Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction (2003) (113)
- Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. (2005) (112)
- Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. (2016) (110)
- Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. (2008) (109)
- Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute (2005) (109)
- Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. (2006) (108)
- Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation (2009) (108)
- Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. (2002) (107)
- CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia (2001) (106)
- Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. (2013) (105)
- Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. (2003) (104)
- Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. (2008) (103)
- Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies. (2019) (102)
- Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. (1991) (101)
- Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. (2011) (101)
- Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes (2011) (100)
- Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. (2010) (98)
- Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome (2012) (95)
- A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. (2011) (95)
- Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. (1992) (94)
- Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. (2016) (93)
- Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. (2015) (91)
- Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. (1997) (90)
- CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. (2002) (90)
- CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. (1997) (89)
- Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. (2002) (89)
- Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. (2009) (89)
- Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. (2016) (87)
- Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease (2009) (86)
- Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma (2002) (86)
- Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. (2012) (84)
- Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. (1990) (83)
- Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome (2018) (83)
- Prediction of veno-occlusive disease using biomarkers of endothelial injury. (2010) (82)
- Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. (2003) (81)
- Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. (2012) (79)
- Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. (2010) (78)
- Active immunotherapy induces antibody responses that target tumor angiogenesis. (2010) (77)
- A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. (2003) (76)
- A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. (1997) (75)
- A Phase 3 randomized study of Remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease. (2020) (75)
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. (2013) (73)
- Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. (2012) (73)
- Does iron overload really matter in stem cell transplantation? (2012) (72)
- Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. (2013) (71)
- Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT (2018) (71)
- Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. (2016) (70)
- Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. (2014) (69)
- Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers (2018) (69)
- Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. (2011) (67)
- Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission (2016) (67)
- Drug safety evaluation of defibrotide (2013) (66)
- Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. (2013) (66)
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (65)
- Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. (2017) (65)
- α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. (2018) (65)
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. (2010) (64)
- Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation (2004) (64)
- Monoclonal Antibody-Purged Autologous Bone Marrow Transplantation Therapy for Multiple Myeloma (1991) (64)
- Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. (2014) (63)
- High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. (2018) (63)
- Isavuconazole Treatment of a Patient with Disseminated Mucormycosis (2014) (62)
- Cord colitis syndrome in cord-blood stem-cell transplantation. (2011) (62)
- Optimistic expectations and survival after hematopoietic stem cell transplantation. (2003) (61)
- Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. (2009) (61)
- T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. (1990) (60)
- Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. (2009) (60)
- A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. (2008) (60)
- Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. (2002) (60)
- BK virus disease after allogeneic stem cell transplantation: a cohort analysis. (2014) (59)
- Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy (2007) (58)
- Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. (2011) (58)
- Clinical evaluation of oral chronic graft-versus-host disease. (2008) (58)
- Fatal hepatic necrosis following imatinib mesylate therapy. (2003) (57)
- Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. (2010) (57)
- Earlier defibrotide initiation post‐diagnosis of veno‐occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation (2017) (57)
- Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. (2005) (57)
- Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells (2005) (57)
- Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation (2008) (56)
- Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. (2016) (56)
- HEPATIC DYSFUNCTION FOLLOWING T‐CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION (1991) (56)
- Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. (2009) (55)
- Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (2012) (54)
- CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. (2011) (54)
- Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. (2008) (54)
- Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies (1993) (54)
- Individual physician practice variation in hematopoietic cell transplantation. (2008) (53)
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (53)
- Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. (2014) (52)
- Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD (2013) (52)
- Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. (2019) (52)
- CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. (2001) (51)
- ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction (2002) (51)
- The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial (2016) (50)
- Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism (2000) (50)
- Variation in supportive care practices in hematopoietic cell transplantation. (2008) (50)
- Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism (2000) (50)
- Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma (2016) (49)
- Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis (2016) (48)
- Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. (1996) (48)
- Expression of CD30 in patients with acute graft-versus-host disease. (2012) (48)
- Immune modulation and chronic graft-versus-host disease (2008) (47)
- Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes (2009) (47)
- HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation (2006) (47)
- Donor-derived second hematologic malignancies after cord blood transplantation. (2010) (47)
- Immune‐Mediated Cytopenia following Bone Marrow Transplantation Case Reports and Review of the Literature (1992) (47)
- Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. (1991) (47)
- An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. (2017) (46)
- Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes (2003) (46)
- CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study (2004) (45)
- Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. (2002) (45)
- Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group (2019) (44)
- The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. (2012) (44)
- Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. (1993) (44)
- Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. (2015) (44)
- Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation (2016) (43)
- Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. (1993) (43)
- A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. (2014) (43)
- Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. (2017) (43)
- Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. (1993) (42)
- Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. (2014) (42)
- Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. (2013) (42)
- Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. (2009) (42)
- Factors associated with bronchiolitis obliterans syndrome and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation (2014) (41)
- Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. (2014) (41)
- Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. (2012) (40)
- Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. (1996) (40)
- Bactericidal/Permeability-Increasing Protein (rBPI21) and Fluoroquinolone Mitigate Radiation-Induced Bone Marrow Aplasia and Death (2011) (39)
- Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. (2019) (39)
- High‐resolution HLA matching in double‐umbilical‐cord‐blood reduced‐intensity transplantation in adults (2009) (39)
- Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. (1997) (39)
- Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. (2011) (39)
- Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. (2020) (39)
- Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity (2005) (38)
- COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies (2021) (38)
- Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. (1998) (38)
- Risk factors for cytomegalovirus reactivation after CD6+ T-cell–depleted allogeneic bone marrow transplantation1 (2002) (37)
- Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. (2015) (36)
- Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease (2004) (36)
- Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. (2021) (36)
- Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease (2012) (36)
- Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation (2021) (36)
- Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. (2009) (35)
- HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. (2021) (35)
- Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. (2000) (35)
- Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. (2013) (35)
- Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes (2010) (34)
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation (1997) (34)
- Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion (2010) (34)
- Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. (2010) (34)
- Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. (2021) (33)
- Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. (2018) (33)
- MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. (2003) (33)
- A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. (2020) (33)
- Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. (2015) (33)
- CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. (1997) (33)
- Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma (2016) (32)
- Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD (2010) (32)
- Donor lymphocyte infusions for acute myeloid leukaemia. (2008) (32)
- Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. (2019) (32)
- Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT (2013) (31)
- Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? (2018) (30)
- Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. (2019) (30)
- Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. (2015) (29)
- Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. (2012) (29)
- A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. (2015) (28)
- Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. (2017) (28)
- CTLA 4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation (2009) (27)
- HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. (2021) (27)
- A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 (2012) (27)
- Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. (2018) (26)
- Chronic graft-versus-host disease: how can we release Prometheus? (2008) (26)
- Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results (2018) (26)
- Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. (2016) (25)
- Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation (2017) (25)
- Characterization of oral involvement in acute graft-versus-host disease. (2011) (25)
- Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control. (2009) (25)
- Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. (2009) (24)
- Defibrotide for the treatment of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome following nontransplant‐associated chemotherapy: Final results from a post hoc analysis of data from an expanded‐access program (2018) (24)
- KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation (2013) (24)
- Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. (2019) (23)
- Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. (2002) (23)
- Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. (2016) (23)
- Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. (2016) (23)
- Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies (2021) (23)
- Chronic myelogenous leukemia. (2004) (22)
- Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation (2010) (22)
- Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study (2013) (22)
- Low dose interleukin‐2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission (2008) (22)
- Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies (2019) (22)
- Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. (1994) (21)
- Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. (2011) (21)
- Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation (2011) (21)
- Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. (2019) (21)
- A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation (2016) (21)
- COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience (2021) (20)
- Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. (2012) (20)
- PERSISTENCE OF MYELOID PROGENITOR CELLS EXPRESSING BCR-ABL MRNA AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA (1994) (20)
- FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation (2011) (19)
- Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse (2022) (19)
- Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. (1995) (19)
- Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD (2013) (19)
- Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. (1996) (18)
- A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (2014) (18)
- Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia (2022) (18)
- Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. (2014) (17)
- Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. (2020) (17)
- Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation (2015) (17)
- White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome (2014) (17)
- A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. (2018) (17)
- Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. (2017) (17)
- Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. (2019) (17)
- Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. (2016) (17)
- Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. (2018) (16)
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. (2019) (16)
- Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. (2011) (16)
- Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. (2017) (16)
- Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation (2014) (16)
- An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. (2016) (15)
- Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia‐negative acute lymphoblastic leukemia in first remission (2016) (15)
- Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients. (2022) (15)
- Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (2017) (15)
- A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT) (2016) (15)
- Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. (2007) (15)
- Excellent Disease-Free Survival after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Only Conditioning Regimen in a Diverse Adult Population. (2005) (14)
- Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation (2019) (14)
- Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy (2002) (14)
- Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. (1994) (14)
- Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. (2017) (14)
- A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. (2016) (13)
- Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. (2013) (13)
- Outcomes and management strategies for graft failure after umbilical cord blood transplantation (2014) (13)
- Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation (2021) (13)
- Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. (2013) (13)
- Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. (1993) (13)
- Donor lymphocyte infusions: the door is open. (1997) (13)
- Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation. (2020) (13)
- Sequential infusion of donor‐derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation (2014) (12)
- Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). (2019) (12)
- In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. (1997) (12)
- T-Cell Depletion to Prevent Graft-vs-Host Disease (2004) (12)
- R24 anti‐GD3 ganglioside antibody can induce co‐stimulation and prevent the induction of alloantigen‐specific T cell clonal anergy (1996) (12)
- Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. (2008) (12)
- Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution (2021) (12)
- Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study. (2018) (12)
- 90Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma (2010) (12)
- A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT) (2018) (12)
- Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. (2017) (11)
- Narrow‐band UVB phototherapy for management of oral chronic graft‐versus‐host disease (2015) (11)
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML (2014) (11)
- Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy (2004) (11)
- The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. (2015) (11)
- A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (2015) (11)
- Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy (2020) (11)
- Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol (2011) (11)
- Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial. (2006) (11)
- Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy (2010) (11)
- Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions (2014) (11)
- Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. (2012) (10)
- Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis. (2007) (10)
- Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? (2016) (10)
- Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active (2021) (10)
- Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment (2020) (10)
- Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies (2021) (10)
- Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease. (2019) (10)
- Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. (2017) (10)
- Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome (2014) (10)
- Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect (2020) (9)
- Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. (2008) (9)
- BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. (2016) (9)
- Invasive fungal disease after remote inoculation in transplant recipients. (2011) (9)
- Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. (2017) (9)
- Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. (2021) (9)
- Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (2020) (9)
- Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC). (2010) (9)
- Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation (2021) (9)
- Stem Cell Transplantation for Hematologic Malignancies (2004) (8)
- IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period (1998) (8)
- Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. (2017) (8)
- Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids as Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease (2017) (8)
- Targeting PI3Kδ function for amelioration of murine chronic graft‐versus‐host disease (2019) (8)
- Evaluating the adverse effects of melphalan formulations (2018) (8)
- Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. (1997) (8)
- Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma (2022) (8)
- Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 (2015) (8)
- SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity (2021) (7)
- What We Have Learned and What We Need to Know (2006) (7)
- Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings (2020) (7)
- Endpoints for Clinical Trials Testing Treatment of Acute Graft- versus-host Disease: A Consensus Document (2010) (7)
- Pooled analysis of Day 100 survival for defibrotide‐treated patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation (2020) (7)
- Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. (2018) (7)
- Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol (2010) (7)
- Limiting conditions for conjugation in Tetrahymena: Cellular development and factor active in conjugation (1980) (7)
- A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease. (2007) (7)
- Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies (2022) (7)
- Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation (2019) (7)
- The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial (2013) (6)
- Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings. (2004) (6)
- Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma (2016) (6)
- The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome (2018) (6)
- Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial (2019) (6)
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study (2019) (6)
- A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation (2020) (6)
- Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens. (2004) (6)
- Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors (2015) (6)
- Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival (2018) (6)
- High‐dose cytosine arabinoside in relapsed and refractory non‐Hodgkin's lymphoma. Limited role as a single agent (1989) (6)
- DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant (2020) (6)
- Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd (2018) (6)
- Chronic myelogenous leukemia. (2005) (6)
- PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
- Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (2021) (6)
- Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. (1995) (6)
- Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis (2021) (5)
- Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies (2014) (5)
- PD-1 modulates regulatory T cell homeostasis during low-dose IL-2 therapy (2017) (5)
- Clinical evaluation of oral chronic graft-versus-host disease (2006) (5)
- Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. (2021) (5)
- Human Bone Marrow Depleted of CD 33-Positive Cells Mediates Delayed but Durable Reconstitution of Hematopoiesis : Clinical Trial of MY 9 Monoclonal Antibody-Purged Autografts for the Treatment of Acute Myeloid Leukemia (2003) (5)
- High Levels of Early Donor Chimerism and Treatment-Responsive Disease Predict Improved Progression-Free Survival Following Non-Myeloablative Transplantation for Advanced CLL. (2005) (5)
- Characterization of Oral Involvement in Acute Graft-Versus-Host Disease (2011) (5)
- 337: Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis (2007) (5)
- Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. (2017) (5)
- Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation (2012) (5)
- Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX) (2021) (5)
- Sirolimus and thrombotic microangiopathy after allogeneic stem cell transplantation (2005) (4)
- Genome Wide Single Nucleotide Polymorphism Typing for Identification of Putative Minor Histocompatibility Antigens in Graft Versus Host Disease. (2006) (4)
- Finding the right academic job. (2009) (4)
- Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease (2010) (4)
- KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation, (2011) (4)
- Phase I Trial of Maintenance Sorafenib after Allogeneic HSCT for Patients with FLT3-ITD AML (2014) (4)
- A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease (2022) (4)
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival (2014) (4)
- Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation. (2006) (4)
- Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation. (2004) (4)
- Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation (2005) (4)
- Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements (2011) (4)
- CD 6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission (1997) (4)
- Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival (2015) (4)
- Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial (2020) (4)
- Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity (2021) (4)
- BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. (2022) (4)
- Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. (2008) (4)
- Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone. (2004) (4)
- Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute. (2020) (4)
- Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. (2021) (4)
- Sirolimus and tacrolimus without methotrexate as graft-vs.-host disease prophylaxis after matched, related peripheral blood stem cell transplantation: low transplant related morbidity and excellent GVHD control (2004) (4)
- Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant? (2020) (4)
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML (2014) (4)
- Validation and Refinement Of The Disease Risk Index For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of 13,131 Patients From The Center For International Blood & Marrow Transplant Research (2013) (4)
- Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study (2013) (3)
- Up-Regulation of α 4 β 7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation (2010) (3)
- Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease (2019) (3)
- Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation (2016) (3)
- HLA-Identical Sibling-Matched, CD34+ Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. (2009) (3)
- GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial (2021) (3)
- Prospective Assessment of Familial Financial Hardship after Hematopoietic Cell Transplantation (2015) (3)
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. (2019) (3)
- Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. (2018) (3)
- graft-versus-host disease Altered B-cell homeostasis and excess BAFF in human chronic (2009) (3)
- Antigen targets of remission-inducing immune therapy are expressed on CML progenitor cells (2010) (3)
- Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation (1995) (3)
- 130: Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis (2008) (3)
- Oral mucositis incidence and severity after methotrexate- and non-methotrexate-containing GVHD prophylaxis regimens (2005) (3)
- Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. (2022) (3)
- Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide (2016) (3)
- Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease (2022) (3)
- Sirolimus and tacrolimus as graft-versus-host disease prophylaxis in allogeneic stem cell transplantation: The Dana Farber Cancer Institute experience (2005) (3)
- Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential (2018) (3)
- BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis (2012) (3)
- Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial (2021) (3)
- GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML). (2006) (3)
- Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients (2013) (3)
- Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease (2017) (3)
- Updated Results from the Ongoing US Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease (2015) (3)
- A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation (2019) (3)
- Philadelphia Chromosome Is Not an Adverse Prognostic Factor in Acute Lymphoblastic Leukemia After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (2011) (3)
- Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival (2014) (3)
- Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (2021) (3)
- HLA mismatch and clinical outcome after unrelated donor (URD) non-myeloablative hematopoietic stem cell transplantation (NST) (2005) (3)
- GM-CSF secreting leukemia cell vaccinations after allogeneic non-myeloablative peripheral blood stem cell transplantation in patients with advanced myelodysplastic syndrome or refractory acute myeloid leukemia (2006) (3)
- Rituxan for steroid-refractory chronic GVHD (2005) (3)
- transplantation in adults depends on reconstitution of thymopoiesis Clearance of CMV viremia and survival after double umbilical cord blood (2013) (2)
- Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation. (2012) (2)
- Impact Of Total Nucleated Cell and CD34+ Cell Dose On Transplant Related Outcomes In Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplants (2013) (2)
- Denileukin diftitox (ONTAK) as targeted therapy against steroid refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) (2004) (2)
- A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation. (2008) (2)
- Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 (2016) (2)
- Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. (2022) (2)
- 31: Comprehensive Typing of 1143 Single Nucleotide Polymorphisms (SNP) in 220 Immunoregulatory Genes Demonstrates That Polymorphisms in CCL3, CCL4 and CCL27 Modulate the Risk of Acute Graft Versus Host Disease (GVHD) (2008) (2)
- Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. (2023) (2)
- CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study (2013) (2)
- Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia (2019) (2)
- Readmissions following umbilical cord blood stem cell transplantation. (2014) (2)
- Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group (2020) (2)
- Defibrotide formulations contain (1→3)-β-D-glucan that could influence clinical diagnostic testing (2020) (2)
- Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report. (2017) (2)
- Improved Immune Reconstitution After Bortezomib-Based Acute Graft-Versus-Host Disease Prophylaxis for HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Allogeneic Transplantation. (2009) (2)
- IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy (2015) (2)
- Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401) (2021) (2)
- Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation. (2005) (2)
- Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis. (2004) (2)
- Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol. (2017) (2)
- Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD) (2016) (2)
- Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis (2022) (2)
- Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease (2019) (2)
- 140: Bortezomib Plus Tacrolimus/Methotrexate for Prophylaxis of Acute GVHD after HLA Mismatched Allogeneic Non-Myeloablative Transplantation: Results of a Dose Finding Phase I Study (2008) (2)
- Defibrotide (DF) for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF. (2005) (2)
- Impaired Immune Reconstitution after Cord Blood Transplantation in Adults Is Associated with Delayed Recovery but Not Functional Impairment of CD8+T Cells. (2007) (2)
- Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program (2015) (2)
- Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data. (2017) (2)
- TRANSPLANTATION Validation and re fi nement of the Disease Risk Index for allogeneic stem cell transplantation (2014) (2)
- Comparison of Tacrolimus and Sirolimus ( Tac / Sir ) versus Tacrolimus , Sirolimus , and mini-methotrexate ( Tac / Sir / Mtx ) as Acute GVHD Prophylaxis after Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (2009) (2)
- Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation. (2006) (2)
- 59: GM-CSF secreting leukemia cell vaccinations after allogeneic reduced-intensity peripheral blood stem cell transplantation (SCT) for advanced myelodysplastic syndrome (MDS) or refractory acute myeloid leukemia (AML) (2007) (2)
- NCCN Practice Guidelines for Chronic Myelogenous Leukemia. (2000) (2)
- Gait speed and recommended treatment intensity among older adults with blood cancers. (2020) (2)
- A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies (2019) (2)
- Pulmonary Clinicopathological Correlation In Long Term Survivors Following Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series (2013) (2)
- Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens (2020) (2)
- Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT). (2006) (2)
- High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS. (2004) (2)
- Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model (2013) (2)
- Genetic Ontogeny Defines Distinct Prognostic Subgroups in AML Patients Age 60 and Older Following Hematopoietic Stem Cell Transplantation (2017) (2)
- Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Leukemias: A Subgroup Analysis from the Defibrotide Expanded-Access Program (2016) (2)
- High Rate of Second Malignancies after Reduced Intensity Double Cord Blood Transplants in Adults. (2008) (2)
- transplantation: a cohort analysis cytomegalovirus reactivation after allogeneic hematopoietic stem cell Sirolimus-based graft-versus-host disease prophylaxis protects against (2011) (2)
- Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd (2018) (2)
- Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease (2019) (2)
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma (2018) (2)
- Immunoproteomic Identification of Graft-Versus-Leukemia Targets in Patients with Chronic Lymphocytic Leukemia. (2007) (2)
- Matching at HLA-C improved the outcomes after double umbilical cord blood transplantation for recipients of 2–4/6 HLA-matched grafts (2017) (2)
- Phase I Study of Ipilimumab (Neutralizing Monoclonal Anti-CTLA4 Antibody) To Treat Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation: Evidence of Tumor Regression without Induction of GVHD. (2006) (2)
- Can IL-15 superagonist ALTer GVL? (2018) (2)
- 209: Practice variation in supportive care in hematopoietic cell transplantation (2007) (2)
- Genetic Predispositions, Management Strategies, and Clinical Outcomes in Adults with Hemophagocytic Lymphohistiocytosis (HLH) after Reduced-Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (HSCT) at Dana-Farber Cancer Institute (2019) (2)
- Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit (2015) (2)
- Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis. (2006) (2)
- The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia (2016) (2)
- Impact of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Blood Cancers (2021) (1)
- BAFF/Blys Levels Correlate with Disease Activity and Alter Peripheral B Cell Subsets in Patients with Chronic GVHD. (2006) (1)
- Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation (2015) (1)
- Biologic Principles of Hematopoietic Stem Cell Transplantation (2006) (1)
- Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis (2019) (1)
- Risk Factors For Readmission Following Allogeneic Hematopoietic Stem Cell Transplantation and Impact On Overall Survival (2013) (1)
- 54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation (2008) (1)
- Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors (2010) (1)
- ORIGINAL ARTICLE Expression of a4b7 integrin on memory CD8 þ T cells at the presentation of acute intestinal GVHD (2013) (1)
- Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation (2015) (1)
- A Bortezomib-Based Regimen Offers Excellent Outcomes In Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: Phase II Results (2013) (1)
- transplantation disease prophylaxis in mismatched related donor or unrelated donor Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host (2013) (1)
- Invasive Yeast Infection After Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. (2022) (1)
- Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens (2013) (1)
- antileukemia responses to donor lymphocyte infusion Reversal of in situ T-cell exhaustion during effective human (2014) (1)
- Infusion of CD 4 Donor Lymphocytes Induces the Expansion of CD 8 Donor T Cells with Cytolytic Activity Directed against Recipient Hematopoietic Cells 1 (2002) (1)
- Decreased Telomerase Activity In CD4 Regulatory T Cells Is Associated with Severity of Chronic Graft-Versus-Host Disease (cGVHD) After Hematopoietic Stem Cell Transplantation (HSCT) (2010) (1)
- Readmissions following allogeneic hematopoietic stem cell transplantation. (2013) (1)
- 2098. Cytomegalovirus (CMV) Infection Following Hematopoietic Cell Transplantation (HCT) with Post-transplant Cyclophosphamide (PTCy): Outcomes in Haploidentical versus Matched or Mismatched Unrelated Donor (MUD/MMURD) Allografts (2022) (1)
- Effective Graft-Versus-Leukemia Responses To Donor Lymphocyte Infusion Are Associated With Preexisting CD8+T Cell Marrow Infiltrates (2010) (1)
- Graft Manipulation to Prevent Graft-vs.-Host Disease (2004) (1)
- Flow Cytometry Analysis of Peripheral Blood CD4+/CD25+/FOXP3+ T Regulator Cells from 11 Patients Treated with Ipilimumab Following Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation. (2007) (1)
- 34: Characterization of B Cell Target Antigens in Patients with Chronic Graft Versus Host Disease (2008) (1)
- A Prospective Study of Iron Overload in Patients Undergoing Ablative Stem Cell Transplantation. (2009) (1)
- Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study (2010) (1)
- Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (2015) (1)
- Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelofibrosis (2014) (1)
- Increasing the Dose of Busulfan Results in Lower Relapse Rates and Higher Non-Relapse Mortality in Patients With MDS/AML Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation (2011) (1)
- Genetic Disparity between Stem Cell Transplant Patients and Their Donors Assessed by High Density Single Nucleotide Polymorphism (SNP) Microarray Typing Is Seen in Specific Genomic Regions. (2004) (1)
- Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) Is Accompanied by Endotoxemia, Activation of Endotoxin-Directed Innate Immunity, and Deficiency of Endogenous Proteins That Limit Endotoxin- Induced TNF Production (2008) (1)
- Topical sirolimus for management of refractory oral chronic graft-versus-host disease. (2020) (1)
- Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation (2019) (1)
- Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells (2008) (1)
- Early Post-Transplant Whole Tumor Cell Vaccination Elicits Anti-Tumor T Cell Responses in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) (2011) (1)
- Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD. (2004) (1)
- Prediction of VOD Using Biomarkers of Endothelial Injury (2009) (1)
- Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation. (2007) (1)
- Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire. (2007) (1)
- Evolution of T Cell Repertoire Diversity After Reduced-Intensity Conditioning and Double Umbilical Cord Blood Transplantation with or without Exposure to FT1050 (16,16-dimethyl Prostaglandin E2) (2013) (1)
- Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation (2023) (1)
- Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial (2015) (1)
- Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease (2016) (1)
- Characterization of Population of HSCT Associated Thrombotic Microangiopathy (TMA) (2017) (1)
- DAPK2 and PIM1 Are Myeloma-Associated Antigens That Elicit Coordinated B and T Cell Immunity After Syngeneic HSCT. (2009) (1)
- GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies (2008) (1)
- Early Clinical Predictors of Hepatic Veno-Occlusive Disease after Myeloablative Hematopoietic Stem Cell Transplantation: A Single-Center Report of 205 Cases (2017) (1)
- Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion. (2009) (1)
- Abstract 2591: Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation (2014) (1)
- Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation (2016) (1)
- Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation (2022) (1)
- Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial (2016) (1)
- Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2014) (1)
- Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease (2021) (1)
- Prognostic value of disease risk score versus gait speed in older adults with lymphoma (2019) (1)
- Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse (2021) (1)
- Response to Helsby and Tingle (2011) (1)
- Phase I Clinical Trial Evaluating Abatacept in Patients with Steroid-Refractory Chronic Graft Versus Host Disease (2017) (1)
- Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT). (2007) (1)
- The Impact of Geographic Proximity to Transplant Center on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation (2010) (1)
- Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells (2013) (1)
- Dynamics of Immune Cell Reconstitution in Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide (PTCy) (2019) (1)
- Abstract CT540: A phase 1 trial of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy with IL-15 superagonist in advanced head and neck cancer: Part 1 results (2022) (1)
- Busulfan Does Intensity and Outcomes in Reduced Intensity Allogeneic Stem Cell Transplantation for MDS/AML (2013) (1)
- T Follicular Regulatory (TFR) Cell Deficiency during Chronic Graft-Versus-Host Disease Is Improved By Low-Dose IL-2 Therapy (2017) (1)
- HLA Locus-Specific Outcomes in Double Umbilical Cord Blood Reduced Intensity Transplantation (DCBT) in Adults. (2007) (1)
- Early Deficiency of Endogenous Proteins Inhibiting LPS-Induced TNF-α Production Correlates with Acute Graft vs Host Disease (aGVHD) after Myeloablative Stem Cell Transplantation (SCT). (2007) (1)
- Measurement and Prevalence of Cognitive Impairment in Older Patients with Hematologic Malignancies (2016) (1)
- Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402) (2018) (1)
- Age Does Not Predict Outcomes For Elderly Patients With Myelodysplastic Syndromes Undergoing Hematopoietic Stem Cell Transplantation With Reduced-Intensity Conditioning (2013) (1)
- Markedly Reduced Overall Survival of CYP2C19 *2/*2 Homozygotes After Myeloablative Hematopoietic Stem Cell Transplantation (2010) (1)
- Proteomics To Identify Novel Immune-Targeted CML Stem Cell Antigens. (2007) (1)
- Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (2020) (1)
- Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. (2022) (1)
- A Phase II Study Of Proteasome-Inhibition For Initial Therapy Of Chronic Graft-Versus-Host Disease (2013) (1)
- 38 Sirolimus and tacrolimus without methotrexate to prevent graft-vs-host disease after matched, related stem cell transplantation (2003) (1)
- A Prospective Phase I/II Trial of Bortezomib-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation: Encouraging Safety, Efficacy, and Survival (2011) (1)
- depleted allogeneic bone marrow transplantation Effect of low-dose interleukin-2 on disease relapse after T-cell- (2011) (1)
- A Novel Transdermal Treatment of Chronic Ocular Graft-Vs-Host Disease (oGvHD): A Phase II Clinic Trial (2020) (1)
- Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd (2022) (0)
- Factor VIII is a potential autosomal B cell minor histocompatibility antigen in chronic GVHD (2010) (0)
- Reply to J.J. Boelens et al. (2018) (0)
- Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality. (2005) (0)
- Cryopreservation of Unrelated Donor Stem Cell Grafts Is Associated with Lower Rates of Chronic Gvhd after Allogeneic Transplantation (2023) (0)
- Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease (2014) (0)
- Production of Antibodies Targeting Surface Membrane Antigens in Patients with Chronic Graft-Versus-Host Disease and Identification of Targeted Antigens (2017) (0)
- Premalignant And Malignant Oral Changes Following Allogeneic Hematopoietic Cell Transplantation (2010) (0)
- Risk Factors for Falls with Injury for Patients Admitted for Hematopoietic Stem Cell Transplant (2014) (0)
- Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd. (2009) (0)
- Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data (2018) (0)
- NK Cell Impairment after Haploidentical Allogeneic Hematopoietic Cell Transplant in Patients Receiving Post-Transplant Cyclophosphamide (PTCy) (2020) (0)
- Therapeutic treatment of multi-organ system, obstructive pulmonary and scleradermatous chronic graft-versus-host disease with the BTK and ITK inhibitor Ibrutinib (TRAN3P.873) (2014) (0)
- Significance of bcr-abl Gene Rearrangement Detected by Polymerase Chain Reaction After Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia (2003) (0)
- in First Complete Remission CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia (2013) (0)
- Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic GVHD: a pilot study (2018) (0)
- Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience. (2004) (0)
- Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies (2020) (0)
- Increased Proliferation of FoxP3 Regulatory T Cells after Allogeneic Hematopoietic Stem Cell Transplantation Is Counterbalanced by Increased Susceptibility to Apoptosis (2008) (0)
- 17: Double Reduced Intensity Cord Blood Transplants in Adults (2007) (0)
- Reply to J. Mehta (2009) (0)
- A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT NOT TUMOR CELLS1 (2001) (0)
- Preparative Regimens in Allogeneic Hematopoietic Cell Transplantation for Malignant Hematological Diseases (2014) (0)
- IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo. (2005) (0)
- An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. (2016) (0)
- Enhanced B-Cell Differentiation and Increased Production of Antibodies Targeting Surface Membrane Antigens in Patients with Chronic Graft-Versus-Host Disease (2016) (0)
- Improved Overall Survival in Patients with Grade III and IV Acute Graft-Versus-Host Disease (2014) (0)
- Differential Plasma Cytokine Levels in Patients with and without Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
- Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease (2014) (0)
- Diverse Patterns of T Cell Reactivity Directed against Multiple Y Chromosome-Derived, HLA a*0201 Restricted, Peptides in Patients with chronic Gvhd (2008) (0)
- Cytokine Profile In Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
- Abstract 6785: Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant induced T cell activation and expansion (2023) (0)
- Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Outcomes Are Not Impaired in Patients of Advanced Age. (2009) (0)
- Efficacy and Safety of Defibrotide in a Subset Analysis of Late-Onset Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Patients from an Ongoing, Expanded-Access Program (2016) (0)
- Activated Circulating T Follicular Helper Cells with Increased Function during Chronic Graft Versus Host Disease after Allogeneic Stem Cell Transplantation (2015) (0)
- Expansion of a CD8+ Temra Population and Activating T-Cell Interactions Characterize the Graft Versus Leukemia Response in Relapsed AML (2022) (0)
- T-cell depletion in allogeneic hematopoietic cell transplantation: Results, barriers, and future directions (2017) (0)
- Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period (2013) (0)
- Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (2018) (0)
- Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease (2018) (0)
- Dendritic Cell/Multiple Myeloma (MM) Fusion Vaccine with Lenalidomide Maintenance after Autologous Hematopoietic Cell Transplant (HCT) Induces MM-Specific Immunity, BMT CTN 1401 (2022) (0)
- Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation. (2009) (0)
- RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma (2011) (0)
- Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. (2012) (0)
- Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study (2018) (0)
- Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Receiving Defibrotide Treatment: A Post-Hoc Analysis (2016) (0)
- 35: High BAFF and BCR-activated B Cells in Patients with Progressive Chronic Graft Versus Host Disease After Rituximab Treatment (2008) (0)
- 2: Identification of Human Minor Histocompatibilty Antigens (mHA) by Combining Bioinformatic Prediction of Peptide Epitopes With Validation of T Cell Reactivity in Patient Blood Samples After Allogeneic Hematopoietic Stem Cell Transplantation (2008) (0)
- A Retrospective Review Comparing Outcomes of Patients Receiving Reinduction Therapy on House Staff and PA Services (2013) (0)
- Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation (2015) (0)
- Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. (2023) (0)
- allogeneic hematopoietic stem cell transplant recipients: a cohort study invasive fungal infections in -Candida other emerging risk factors of non Infliximab use in patients with severe graft-versus-host disease and (2011) (0)
- Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease. (2023) (0)
- Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab (2020) (0)
- Adoptively Transferred Healthy Donor Treg Expand and Durably Persist in IL-2 Treated Patients with Refractory Chronic GVHD (2021) (0)
- HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation. (2005) (0)
- Sequence-Based Discovery of Novel Bacteria, Bradyrhizobium Enterica, in Cord Colitis Syndrome (2013) (0)
- The Graying of Clinical Transplantation (2006) (0)
- TRANSPLANTATION Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease (2017) (0)
- stem cell transplantation veno-occlusive disease in patients who undergo myeloablative allogeneic Prior gemtuzumab ozogamicin exposure significantly increases the risk of (2013) (0)
- transplantation assessment of hematopoietic chimerism after allogeneic stem cell based method for - A novel rapid single nucleotide polymorphism (SNP) (2013) (0)
- Single Cell T Cell Maps of Donor Lymphocyte Infusion (DLI) Response and Resistance (2019) (0)
- Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (2020) (0)
- Patient Characteristics Associated With Receiving Hematopoietic Stem Cell Transplantation In An Older, Transplant-Appropriate MDS Cohort: The MDS-TAO Study (2013) (0)
- Recovery A fter S tem-Cell T ransplantation f or Hematologic D iseases (2001) (0)
- 25. Immunogenicity and Reactogenicity of COVID-19 mRNA Vaccines in Allogeneic Stem Cell Transplant Recipients (2021) (0)
- Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study (2022) (0)
- Telomerase Activity in Regulatory T Cells is Inversely Associated With Severity of Chronic Graft-Versus-Host Disease (cGVHD) After Hematopoietic Stem Cell Transplantation (HSCT) (2011) (0)
- THE ASSOCIATION OF FUNCTION, MOOD, AND LONELINESS WITH SURVIVAL IN OLDER ADULTS WITH HEMATOLOGIC MALIGNANCIES (2018) (0)
- Abstract 17: In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation (2017) (0)
- Challenges in Implementing NIH Chronic Graft-Versus-Host Disease Diagnosis and Severity Criteria in a Large Multi-Center Prospective Study: Secondary Analysis From the Phase III ATLG Trial (2018) (0)
- Pre-Emptive Rituximab for the Prevention of EBV-Related PTLD in Umbilical Cord Blood Transplantion Patients (2011) (0)
- Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease (2016) (0)
- Preventing, Treating Relapse After ASCT in Hematologic Malignancy Patients (2017) (0)
- Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: A Concordance Analysis Between Day+100 Complete Response and Survival (2016) (0)
- New Guidelines Help Health Professionals Recognize and Manage Late Complications (2006) (0)
- rotective Antibody Responses to Pneumococcal onjugate Vaccine after Autologous Hematopoietic tem Cell Transplantation (2005) (0)
- Abstract B72: Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who received Ipilimumab post GVAX vaccine. (2016) (0)
- Immunosuppression Taper to Induce Graft-Verus-Tumor Activity As the Sole Therapy for Early Relapse after Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (2014) (0)
- OI0444 Biomarkers in oral chronic graft-vs-host disease (2014) (0)
- Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin (2014) (0)
- Low Dose IL-2 Therapy in Patients with Chronic Gvhd Induces PD-1+treg That Are Highly Activated, Immune Suppressive, and Proapoptotic (2022) (0)
- Outcomes of 40 Adult Patients after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Conditioning Regimen. (2006) (0)
- Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (0)
- Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients (2021) (0)
- Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion (2012) (0)
- Differences in Medical Decision Making in Adult and Pediatric Hematopoietic Stem Cell Transplantation (HCT). (2006) (0)
- Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial (2022) (0)
- Results in Superior Patient Outcome Compared to Myeloablative Conditioning Regimen for Single-Unit Umbilical Cord Blood Transplantation in Hematological Malignancies (2016) (0)
- Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience (2021) (0)
- Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes: A Multicenter Validation Study (2008) (0)
- Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL) (2018) (0)
- Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity. (2005) (0)
- Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant (2018) (0)
- Safety And Clinical Efficacy Of Early Vaccination After Nonmyeloablative Transplant For Advanced Chronic Lymphocytic Leukemia (2010) (0)
- Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with Synchronous CNS Involvement (2016) (0)
- Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation (2019) (0)
- Inhibiting EZH2 function prevents and treats chronic graft vs host disease (cGVHD) by disrupting germinal center formation and plasma cell maturation (2019) (0)
- Low Dose Busulfan Is Associated with Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation. (2012) (0)
- Biotherapy Order Entry (BOE) – Electronic Physician Orders for Cellular Therapy Products (2011) (0)
- Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation. (2006) (0)
- Early Post-Transplant Whole Tumor Cell-Based Vaccination Alters the Kinetics of T Cell Reconstitution (2012) (0)
- ORAL HEALTH STATUS AND RISK OF BACTEREMIA IN PATIENTS UNDERGOING MYELOABLATIVE OGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (2017) (0)
- Comparative Effectiveness Analysis Of CD34+Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts On Allogeneic Hematopoietic Cell Transplantation For Patients With Acute Myeloid Leukemia (AML) In Complete Remission (2010) (0)
- Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation (2020) (0)
- Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
- Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) after Chimeric Antigen Receptor T-Cell Therapy Failure (2022) (0)
- Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. (2023) (0)
- Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies (2014) (0)
- Regulation of Apoptotic Pathways in Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2013) (0)
- Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial (2020) (0)
- A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation (2011) (0)
- Reducing Inappropriate Testing Following NCCN and IDSA Guidelines in Autologous Stem Cell Transplant (SCT) Patients (2013) (0)
- Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease (2012) (0)
- Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire (2013) (0)
- 7: Long-term outcome of methotrexate-free GVHD prophylaxis using sirolimus and tacrolimus in matched related (MRD) and unrelated donor (URD) peripheral blood stem cell transplantation (PBSCT) (2007) (0)
- Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B And T Cell Immunity After Donor Lymphocyte Infusion (2010) (0)
- Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens (2012) (0)
- Effects of Daily Low Dose IL-2 Therapy on Homeostatic Regulation of CD4+Foxp3+ Regulatory T Cells In Patients with Chronic Graft-Versus-Host Disease (2010) (0)
- B Cells Are Primed for Survival by BAFF-Driven Bim Degradation In Chronic Graft Versus Host Disease (cGVHD) Patients (2010) (0)
- Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT) (2011) (0)
- Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? (2021) (0)
- Does Iron Overload Really Matter in Stem Cell Transplantation (2011) (0)
- 71. Validation of Manufacturing NKG2D Chimeric Antigen Receptor T Cells for a First-In-Human Clinical Trial in AML/MDS and Multiple Myeloma (2016) (0)
- Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation. (2005) (0)
- phase 2 trial after allogeneic peripheral blood stem cell transplantation: results of a Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD (2014) (0)
- Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid Disorders (2010) (0)
- Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates (2014) (0)
- Adenovirus Infection Following Hematopoietic Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCy): Outcomes in Haploidentical Versus Matched or Mismatched Unrelated Donor (MUD/ MMURD) Allografts (2023) (0)
- Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease (2015) (0)
- What a "harmless" antibiotic can teach us about GVL. (2022) (0)
- Topical Dexamethasone/Tacrolimus for Management of Oral Chronic Graft-Versus-Host Disease (2009) (0)
- Primum non nocere: allo-HSCT for AML in CR1. (2021) (0)
- Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9. (2006) (0)
- 332: Effective graft-versus-leukemia responses are associated with the presence of nucleic acid-immunoglobulin complexes that stimulate toll-like receptors (TLR) 8 and 9 (2007) (0)
- Distinct peptide specificities of coordinated T and B cell immune response to DBY minor histocompatibility antigen following allogeneic stem cell transplantation (2003) (0)
- Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease, (2011) (0)
- Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4 (2014) (0)
- Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial (2017) (0)
- allogeneic bone marrow transplantation Defective activation of mitogen-activated protein kinase after (2011) (0)
- Graft-versus-Host Disease : The Pesky Fly in the Ointment (2007) (0)
- Depression and anxiety before hematopoietic stem cell transplantation are associated with increased mortality (2003) (0)
- transplantation in chronic myelogenous leukemia polymerase chain reaction after allogeneic bone marrow Clinical significance of bcr-abl gene rearrangement detected by (2011) (0)
- Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT). (2006) (0)
- Quantitative CT Square Root Of Wall Area At Pi10 (mm) Correlates With Lung Function And The Development Of Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
- Targeting the CD6-Alcam Pathway to Prevent and Treat Graft Vs Host Disease (2020) (0)
- Cord Colitis: An Antibiotic-Responsive Colitis Syndrome Following Cord Blood Stem Cell Transplantation (2010) (0)
- Expression of α4β7 Integrin on Peripheral Blood Memory CD4+ T-Cells After Allogeneic HCT Correlates with Non-Relapse Mortality and Overall Survival (2012) (0)
- The Effect of FLT3 and NPM1 Mutation Status on Outcomes of Transplanted Vs. Non-Transplant Treated Elderly Patients with Normal Karyotype AML: A Retrospective Multicenter Study (2016) (0)
- Post Hoc Analysis of Defibrotide for Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation in Subgroups of Patients with and Without Leukemia (2017) (0)
- Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study (2010) (0)
- Getting Ready for Engineered Cell Therapies—an Administrative Perspective (2017) (0)
- Maintenance of Naïve T Cells and a Diverse TCR Repertoire Are Critical for Reconstitution of EBV-Specific Immunity after Double Cord Blood Transplantation (2014) (0)
- Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center (2015) (0)
- Cytomegalovirus Reactivation Does Not Reduce the Risk of Disease Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (2016) (0)
- Anti-HLA Antibodies Predict Graft Failure, Time to Engraftment and Umbilical Cord Unit Dominance in Double Umbilical Cord Blood Transplantation (2011) (0)
- Caregiver Quality of Life As Reported By Patients after Hematopoietic Cell Transplantation (2022) (0)
- Cytokine Release Syndrome Severity Following Haploidentical Stem Cell Transplant Is Not Associated with the Measured Cellular Content of Peripheral Blood Stem Cell Grafts (2023) (0)
- Outcomes of Patients Older Than Age 70 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies (2013) (0)
- A342 Endothelial Stress Markers in Multiple Myeloma Patients (2009) (0)
- Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome (2010) (0)
- Cytokine Release Syndrome Post HLA-Mismatched Stem Cell Transplantation Does Not Affect Immune Reconstitution and Is Effectively Treated with Tocilizumab (2022) (0)
- 103Engraftment, GVHD, immune reconstitution and survival following CD8+ T cell depleted allogeneic peripheral blood stem cell transplantation (PBSCT) (2003) (0)
- Outcomes for Patients with IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (2021) (0)
- myelogenous leukemia after allogeneic bone marrow transplantation for chronic Persistence of myeloid progenitor cells expressing BCR-ABL mRNA (2011) (0)
- Lower Incidence of Chronic GVHD Observed after Transplantation with Cryopreserved Unrelated Allogeneic Stem Cells. (2023) (0)
- Mitochondrial DNA Mutations Distinguish Individual Donor- and Recipient-Derived Immune Cells Following Matched Unrelated Allogeneic Stem Cell Transplantation (2021) (0)
- Recombinant Bactericidal Permeability Increasing Protein (rBPI21) For Endotoxin (Lipopolysaccharide, LPS) Neutralization During Hematopoietic Stem Cell Transplantation (HSCT): Phase I/II Clinical Trial Results (2010) (0)
- Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates (2019) (0)
- Low-Dose Administration of Recombinant IL-2 Following T Cell Depleted Bone Marrow Transplantaion Induces Expansion of CD4+CD25+ FOXP3+ Regulatory T Cells in Vivo. (2004) (0)
- 129Enhanced T-cell neogenesis following non-myeloablative adult allogeneic hematopoietic stem cell transplantation (NM-HSCT) (2003) (0)
- Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL) (2019) (0)
- Long term outcome of patients with mantle cell lymphoma following autologous stem cell transplantation (2005) (0)
- mpact of Conditioning Regimen Intensity n Outcome of Allogeneic Hematopoietic Cell ransplantation for Advanced Acute Myelogenous eukemia and Myelodysplastic Syndrome (2006) (0)
- Homeostatic Mechanisms Affect Reconstitution Of CD4+ FoxP3+ Regulatory T Cells After Hematopoietic Stem Cell Transplantation (2009) (0)
- Elevated B cell activating factor (BAFF) in patient plasma after allogeneic stem cell transplantation is a potential biomarker for chronic graft versus host disease (2006) (0)
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (0)
- Non-Myeloablative Allogeneic Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism. (2007) (0)
- Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP). (2012) (0)
- A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease (2012) (0)
- To induce, or not to induce, that is the (still unanswered) question. (2012) (0)
- Donor Source and Gvhd Prophylaxis Impact Risk of Acute Renal Injury in the Peri-Engraftment Period after Allogeneic Stem Cell Transplantation (2022) (0)
- New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
- tumor destruction Protein disulfide isomerases are antibody targets during immune-mediated (2013) (0)
- Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets (2022) (0)
- Allogeneic B cell response to H-Y minor histocompatibility antigens after donor lymphocyte infusion correlates with disease response (2005) (0)
- Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation (2020) (0)
- Sirolimus and tacrolimus without methotrexate as graft-vs.-host disease prophylaxis after matched, unrelated peripheral blood stem cell transplantation (PBSCT): Excellent GVHD control with low transplant-related morbidity and mortality (2006) (0)
- Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia (2018) (0)
- Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) (2012) (0)
- Adapting Virtual Care in a Global Pandemic: Telemedicine As a Useful Alternative in Clinical Practice in the Stem Cell Transplant Program at Dana-Farber Cancer Institute (2021) (0)
- Markers of Angiogenesis and Neovascularization Correlate with Functional Recovery of Thymic Epithelial Cells and T Cell Immune Reconstitution After Cord Blood Transplantation in Adults (2013) (0)
- Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response. (2004) (0)
- The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction (2013) (0)
- Prediction of VOD Using Biomarkers of Endothelial Injury. (2008) (0)
- transplantation Prostaglandin-modulated umbilical cord blood hematopoietic stem cell (2014) (0)
- MATERIALS AND METHODS Patients Patients with active cGVHD following allogeneic stem cell transplantation at the Dana-Farber Cancer Institute and the Brigham and Women ’ s Hospital Stem Cell Transplant (2002) (0)
- OI0447 Narrow-band UV-B phototherapy for management of oral chronic graft-vs-host disease (2014) (0)
- Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Subset Analysis Results from an Ongoing Expanded Access Program (2016) (0)
- Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution (2020) (0)
- HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis (2011) (0)
- A Systematic Approach to Providing Safe Quality Care for Patients Receiving Engineered, Non-Stem Cell Therapies (2016) (0)
- The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors. (2004) (0)
- 181: Identification of Graft-Versus-Myeloma Target Antigens following Syngeneic Hematopoietic Stem Cell Transplantation (2008) (0)
- concentrations (see comments) Recombinant interleukin-2 infusions and decreased IgG2 subclass (2011) (0)
- Primary Care Referrals for Suspected Hematologic Malignancies: Incidence, Factors Affecting Choice of Specialist, and Flow of Referral Information. (2010) (0)
- Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to graft-versus-leukemia (2020) (0)
- No Change in Viral Infections, But Low Relapse Rate, with the Elimination of Anti-Thymocyte Globulin Prior to Double Umbilical Cord Blood Transplantation (2017) (0)
- TRANSPLANTATION Ef fi cacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease (2016) (0)
- Myeloablative Flu/Bu Conditioning Provides Similar Overall Survival and Lower Non-Relapse Mortality Compared to Traditional Bu/Cy or Cy/TBI in Allogeneic Transplantation (2017) (0)
- A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). (2019) (0)
- Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2012) (0)
- Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia. (2009) (0)
- TRANSPLANTATION Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease (2015) (0)
- Naïve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap. (2022) (0)
- Ex Vivo Treatment of Umbilical Cord Blood with Prostaglandin E2 Alters the Molecular and Functional Properties of T Cells Via Modulating Wnt/β-Catenin Signaling (2013) (0)
- igh-dose Therapy with Single Autologous ransplantation versus Chemotherapy for Newly iagnosed Multiple Myeloma : A Systematic Review nd Meta-analysis of Randomized Controlled Trials (2007) (0)
- Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells (2014) (0)
- Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation (2011) (0)
- Comparison of methotrexate- versus sirolimus-containing graft-versus-host disease prophylaxis regimens after myeloablative stem cell transplantation (2006) (0)
- lymphocytes from patients with hematologic and solid malignancies Interleukin-12 augments cytolytic activity of peripheral blood (2011) (0)
- Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS (2022) (0)
- Defective populations of regulatory T cells correlate with the occurrence of chronic graft versus host disease after allogeneic stem cell transplantation (2004) (0)
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation (2012) (0)
- transplantation and primary biliary cirrhosis hematologic malignancies after allogeneic hematopoietic stem cell Differential epitope mapping of antibodies to PDC-E2 in patients with (2013) (0)
- Abstract 3371: Mapping the evolution of T cell states during DLI response and resistance using single-cell data and computational tools (2019) (0)
- The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert J. Soiffer?
Robert J. Soiffer is affiliated with the following schools:
